Pricing Log in Create free account
Friday 6 November 2026 Export AZTA’s income statement to Excel — free account

Azenta, Inc.

AZTA Healthcare Medical Instruments & Supplies

Azenta, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $593.8 million, up 3.55% from fiscal 2024.

Revenue
+12.0%
EPS
+104.4%
Free cash flow
−134.7%

Quarter to June 2026, against a year earlier

37.47 1.67 −4.27%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
−10.9×
Dividend yield
—
F-score
7/9
Altman Z
3.85
Beneish M
−2.63
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.17
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — 1 — 1 — — — —
Sell — — — — — — — — — — — —
Insider Ownership 4.78%

Capital & Financial Ratios $m

Size
Market Cap 1,640.00
Revenue ttm 613.81
Net income ttm (122.90)
Free cash flow ttm 9.88
Net debt Q (328.21)
Valuation
P/E 0.00
Forward P/E (10.90) (negative: loss-making)
Price / sales 2.76
Forward P/S Powerpack
Price / FCF 171.73
Price / book 1.12
Financial health
Current ratio Q 2.50 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (0.42)
Growth
Revenue growth Q +12.04% (above 0%: growing)
Operating income growth Q −125.84% (below 0%: shrinking)
EPS, this year −37.64% (below 0%: weak)
EPS, next year A +50.14% (at or above 15%: strong)
Revenue, next year A +3.53%
EPS, past 5 yrs —
EPS, next 5 yrs A +10.86%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.3×, against a ten-year median of 3.7×; over the ten years it ranged from 1.1× in 2026 to 60.0× in 2021.
P/S against its own 10 years 23.69%
10-year low 10-year high
P/B against its own 10 years 23.25%
10-year low 10-year high
EV/Sales against its own 10 years 23.47%
10-year low 10-year high
EV/FCF against its own 10 years 91.70%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—
Growth, 2016–24
−100.0%/yr
  1. 0.40 ’16
  2. 0.40 ’17 +0
  3. 0.40 ’18 +0
  4. 0.40 ’19 +0
  5. 0.40 ’20 +0
  6. 0.40 ’21 +0
  7. 0.00 ’22 −100
  8. 0.00 ’23
  9. 0.00 ’24
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,022 433 343 328
Receivables 157 178 152 150
Inventory 128 71 75 79
Other 13 99 74 71
1,419 833 708 681
2023 2024 2025 Q'26
Payables 36 33 38 39
ST’ Debt — — — —
Other 158 32 62 58
211 206 238 273

Compound Annual Growth %

10y 5y 3y
Sales 0.72% 8.85% 2.25%
Cash Flow 5.14% 13.77% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 10.57% 7.31% (19.92%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY26 Estimate 0.11 Actual 0.09

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY25 0.09 0.05 Miss by 0.04
Q3 FY25 0.13 0.19 Beat by 0.06
Q4 FY25 0.21 0.21 Met by 0.00
Q1 FY26 0.11 0.09 Miss by 0.02

EPS $

Dec Mar Jun Sep Year
’26 (0.34) (3.49) 0.05 — —
’25 (0.25) (1.04) (1.05) 1.11 (1.22)
’24 (0.28) (2.47) (0.12) (0.14) (3.09)
’23 (0.15) (0.07) (0.02) 0.06 (0.22)
’22 0.58 28.15 (0.13) (0.28) 28.48
’21 0.35 0.32 0.53 0.29 1.49
’20 0.18 0.12 0.19 0.39 0.88
Fiscal quarters ending in the months shown.

Revenue $m

Dec Mar Jun Sep Year
’26 149 145 161 — —
’25 147 143 144 159 594
’24 142 136 144 151 573
’23 178 148 166 59 551
’22 140 146 133 138 555
’21 118 130 129 137 514
’20 211 220 220 (263) 389
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Dec Mar Jun Sep Year
’26 21 14 1 — —
’25 30 14 26 2 72
’24 14 9 10 18 50
’23 (27) (12) 17 28 6
’22 16 (71) (420) 10 (466)
’21 44 34 45 27 150
’20 26 (66) 26 52 38
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Dec Mar Jun Sep Year
’26 15 6 (5) — —
’25 22 7 15 (6) 38
’24 2 0 1 8 12
’23 (40) (21) 9 18 (34)
’22 (3) (101) (435) (4) (543)
’21 29 24 36 9 97
’20 16 (77) 18 42 (2)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to September

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 434 527 632 334 389 514 555 551 573 594 614 +3.5% 615 639 677 +4.5%
Gross margin, % 36.10 37.70 38.96 40.28 44.31 47.46 46.01 43.38 44.40 45.52 44.05 +9.4 pt
EBT (18) 15 20 (84) (40) (49) (10) (20) (19) (7) (152) (9.8%)
EBT margin, % (4.18) 2.75 3.24 (25.12) (10.37) (9.53) (1.79) (3.63) (3.34) (1.20) (24.81) +3.0 pt
Net income (69) 63 116 437 65 111 2,133 (15) (165) (56) (123) (2.4%)
Per share, $
Per share, $ Revenue 6.34 7.58 8.96 4.64 5.28 6.92 7.42 8.32 10.78 12.98 13.55 +8.3%
Earnings (1.01) 0.90 1.65 6.08 0.88 1.49 28.48 (0.22) (3.09) (1.22) (2.67) +2.1%
Cash flow 0.58 1.38 1.05 1.26 0.51 2.02 (6.22) 0.09 0.94 1.58 0.84 +11.8%
Capex (0.15) (0.18) (0.18) (0.33) (0.54) (0.71) (1.03) (0.60) (0.70) (0.74) (0.62) +19.7%
Free cash flow 0.43 1.20 0.87 0.93 (0.03) 1.31 (7.26) (0.51) 0.23 0.84 0.22 +7.7%
Book value 8.08 8.73 10.18 15.82 16.50 17.85 44.91 38.25 33.25 37.75 33.35 +18.7%
Shares, m 69 70 70 72 74 74 75 66 53 46 46 (4.4%)
Valuation, ×
Valuation, × P/E 0.00 34.69 20.89 6.11 52.57 68.69 1.51 0.00 0.00 0.00 0.00 18.4
P/S 2.15 4.12 3.85 7.98 8.76 14.81 5.78 5.98 4.06 2.21 2.76 6.0
P/B 1.68 3.57 3.38 2.34 2.80 5.74 0.95 1.30 1.32 0.76 1.12 2.4
EV/Sales 1.97 3.94 3.77 7.13 8.24 14.45 2.35 4.22 3.39 1.72 2.31 5.1
EV/FCF 28.95 24.87 38.81 35.52 (1,556.10) 76.49 (2.41) (69.20) 157.54 26.63 143.59 (123.9)
Cash, $m
Cash, $m Operating cash flow 40 96 74 91 38 150 (466) 6 50 72 38 +6.9%
Capex (10) (13) (13) (24) (40) (53) (77) (39) (37) (34) (28) +14.5%
Free cash flow 30 83 61 67 (2) 97 (543) (34) 12 38 10 +2.9%
Balance, $m
Balance, $m Working capital 180 205 399 375 438 432 2,229 1,208 627 471 409 +11.3%
Net debt (85) (102) (48) (285) (200) (185) (1,953) (1,022) (433) (343) (328) +16.8%
Shareholders’ equity 554 608 718 1,139 1,214 1,325 3,363 2,535 1,768 1,727 1,510 +13.5%
Returns, %
Returns, % ROA (9.62) 8.62 12.52 33.50 4.22 6.56 77.06 (0.44) (6.61) (2.68) (6.31) +6.9 pt
ROIC (2.27) 1.77 2.93 (3.47) (2.26) (1.70) (1.10) (2.53) (2.40) (1.21) (9.27) +1.1 pt
ROE (11.72) 10.78 17.59 47.12 5.51 8.72 90.98 (0.50) (7.67) (3.19) (7.72) +8.5 pt
People
People Employees 1,310 1,661 1,548 2,984 3,200 2,800 3,100 3,500 3,300 3,000 — +9.6%
Revenue/emp, $m 0.33 0.32 0.41 0.11 0.12 0.18 0.18 0.16 0.17 0.20 — (5.6%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Azenta, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PLSE Pulse Biosciences, Inc $3.9B — (loss-making) — (loss-making) +359.30% (above 0%: growing) n/m −1,180.54% (below 0%: shrinking) 51.65% (6,149.87%) Compare
STVN Stevanato Group S.p.A. $3.6B 22.4× 30.2× +5.91% (above 0%: growing) +17.53% (above 0%: growing) +4,089.92% (above 0%: growing) 29.12% 18.51% Compare
WRBY Warby Parker Inc. $3.2B 434× 208× +10.40% (above 0%: growing) −20.00% (below 0%: shrinking) −30.28% (below 0%: shrinking) 54.41% 1.45% Compare
ATRC AtriCure, Inc. $3.1B 199× 573× +15.03% (above 0%: growing) n/m −0.73% (below 0%: shrinking) 77.27% 2.82% Compare
XRAY DENTSPLY SIRONA Inc. $2.0B — (loss-making) 24.5× −7.52% (below 0%: shrinking) n/m −17.95% (below 0%: shrinking) 52.99% 4.43% Compare
LMAT LeMaitre Vascular, Inc. $1.9B 29.7× 28.2× +11.34% (above 0%: growing) −14.29% (below 0%: shrinking) −25.78% (below 0%: shrinking) 71.66% 26.03% Compare
KMTS Kestra Medical Technologies, Ltd. $1.7B — (loss-making) — (loss-making) +59.88% (above 0%: growing) n/m −17.75% (below 0%: shrinking) 56.50% (121.59%) Compare
AZTA Azenta, Inc. $1.6B — (loss-making) — (loss-making) +12.04% (above 0%: growing) n/m −134.69% (below 0%: shrinking) 44.89% (2.59%)
STAA STAAR Surgical Company $1.3B — (loss-making) 84.4× −11.95% (below 0%: shrinking) −38.89% (below 0%: shrinking) +1,378.70% (above 0%: growing) 70.90% 6.54% Compare
Median of peers $2.6B 114× 57.3× +10.87% −17.14% −17.85% 55.46% 3.63%

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 18 December 2025

Ownership

Directors and executive officers, together 10.90%
BlackRock, Inc., 13.50%
The Vanguard Group, Inc., 12.30%
Quentin Koffey 10.10%
Politan Capital Management LP, 10.00%
Dimensional Fund Advisors LP, 6.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Azenta, Inc. (AZTA) Latest News

30 Oct

Impact 3 · · PR Newswire

28 Oct

Impact 3 · · PR Newswire

18 Oct

Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.

24 Aug

Impact 3 ·

19 Aug

Impact 3 ·

12 Aug

Impact 3 ·

11 Aug

Impact 4 · · The Motley Fool transcript

6 Aug

Impact 4 ·
Impact 4 ·

5 Aug

Impact 3 · transcript
Impact 3 · · MarketBeat
Impact 3 · · Moby transcript

4 Aug

Impact 4 ·
Impact 3 ·

3 Aug

Impact 4 ·

8 Jul

Impact 3 ·

16 May

Impact 3 · · StockStory

6 May

Impact 4 · · Moby
Impact 4 · · MarketBeat

5 May

Impact 4 · · PR Newswire

3 May

Impact 3 · · Simply Wall St.

28 Apr

Impact 3 · · Insider Monkey

7 Apr

Impact 4 · · PR Newswire

16 Mar

Impact 4 · · Simply Wall St.

12 Mar

Impact 4 · · MarketBeat

6 Mar

Impact 4 · · MarketBeat

4 Mar

Impact 4 · · PR Newswire
Impact 4 · · Simply Wall St.

3 Mar

Impact 3 · · StockStory
stockrow.com/AZTA · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com